Abstract 344P
Background
Breast cancer imposes a significant regional and global health burden not only due to being the most prevalent malignancy in females in the Middle East and worldwide, but due to the associated substantial morbidity and mortality. Therefore, the determination of the epidemiological features of breast cancer in the Middle East is of prominent interest given the significant resultant burden associated with breast cancer as it enables for the efficient introduction of effective interventions.
Methods
Data on 20,046 female patients of different nationalities and residing in Jordan diagnosed with breast cancer during the period of 2000-2018 were obtained from the Jordan Cancer Registry. Consequently, comprehensive statistical analysis was performed to establish the epidemiological characteristics of breast cancer in Jordan, including the overall survival and crude incidence.
Results
A total of 20,046 female patients with a mean age of 51.5 ± 12.5 years old were included in the analysis. Only 6.54% of the enrolled patients were smokers at the time of diagnosis. Breast cancer was more commonly affecting the left breast, 46.9% of the patients, than the right breast, 43.5% of the patients, whereas 1.18% of the patients had breast cancer bilaterally. The upper outer quadrant of the breast was the most commonly reported site of tumour location. Moderately differentiated carcinoma was the most commonly encountered grade in 31.4% of the patients, whereas 28.9% had poorly differentiated carcinoma. Regional spread to the lymph nodes was observed in 19.0% of the sample and 13.1% of the patients had distant metastasis, while localized breast cancer was noted in 16.6% of the patients. A statistically significant increase in the crude incidence of breast cancer in females has been observed in Jordan over the 18 years period with a crude incidence estimated effect of 0.46 (P-value<0.001). The overall survival rate was determined to be 95.8%, 83.2%, and 62.8% at 1-year, 3-year, and 5-year interval, respectively.
Conclusions
Breast cancer in Jordan imposes a significant burden due to the significant increase in the crude incidence over the 18-year period, and thus mandating vigorous and vigilant screening and preventative measures.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC
Presenter: Miguel Martin Jimenez
Session: Poster session 03
414P - Trastuzumab deruxtecan for HER2-positive breast cancer brain metastasis: A systematic review and meta-analysis
Presenter: Isabella Michelon
Session: Poster session 03
415P - Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)
Presenter: Linda Cucciniello
Session: Poster session 03
416P - Cost-effectiveness of first-line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): Analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)
Presenter: Sandeep Sehdev
Session: Poster session 03
417P - New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
Presenter: Viola Cogliati
Session: Poster session 03
418P - Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer
Presenter: Qingyuan Zhang
Session: Poster session 03
419P - Aspire to ASCENT: Real-world outcomes from patients with metastatic triple-negative breast cancer (mTNBC) treated with Sacituzumab govitecan (Saci) in a single academic institution
Presenter: Elaine Walsh
Session: Poster session 03
421P - Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer
Presenter: Takayuki Iwamoto
Session: Poster session 03
422P - UK real-world data (RWD) of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) use in metastatic breast cancer (MBC)
Presenter: Georgina Gullick
Session: Poster session 03
423P - A real-world study on the clinical value of apatinib-based regimens in metastatic triple-negative breast cancer
Presenter: Huang wei
Session: Poster session 03